Showing results (61-70 of 307) with videos related to

Sort By:
Pageof 31
Clinical Neuropharmacology|October 27, 2009
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effectsKelly E Lyons, Joseph H Friedman, Neal Hermanowicz, et al.
Expert Opinion on Pharmacotherapy|March 26, 2025
Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switchingStuart H Isaacson, Henry Nasrallah, Rajesh Pahwa, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's diseaseRobert A Hauser, Nicholas H G Holford
Movement Disorders : Official Journal of the Movement Disorder Society|September 25, 2004
Parkinson's disease home diary: further validation and implications for clinical trialsRobert A Hauser, Frieda Deckers, Philippe Lehert
Movement Disorders : Official Journal of the Movement Disorder Society|November 13, 2009
Levodopa response in early Parkinson's diseaseRobert A Hauser, Peggy Auinger, David Oakes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 30, 2014
Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRSWerner Poewe, Robert A Hauser, Anthony Lang, et al.
International Journal of Psychiatry in Clinical Practice|May 16, 2022
Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosisMarwan Sabbagh, Gary W Small, Stuart H Isaacson, et al.
Neurology and Therapy|July 29, 2022
Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert PanelRajesh Pahwa, Stuart H Isaacson, Gary W Small, et al.
Pageof 31